ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
119.006,93
0,13%
S&P 500
5.836,22
0,16%
US Dollar vs BRL
6,0945
-0,01%
Bitcoin
95.465,50
1,01%
Brent Oil
79,895
-0,48%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCC)

  7. Cyclacel Pharmaceuticals Inc (CYCC) Notícias

CYCC

Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYCC
DataHoraFonteTítuloCódigoCompanhia
03/01/202511:01GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarNASDAQ:CYCCCyclacel Pharmaceuticals Inc
05/12/202418:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/11/202418:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/11/202414:22GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
12/11/202418:45GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
24/10/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleNASDAQ:CYCCCyclacel Pharmaceuticals Inc
23/10/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
09/10/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
25/09/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/09/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/09/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/08/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/08/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
26/06/202410:15GlobeNewswire Inc.Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/06/202409:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/06/202409:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/05/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/05/202417:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202414:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202408:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/04/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/03/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/03/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/02/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/01/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
18/12/202311:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYCC

Seu Histórico Recente

LSE
0GOZ
Zkb Gold Etf Aa Chf
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados